Rapamycin for Heart Failure
This proof-of-concept pilot study investigated the effects of rapamycin (RAPA) on cardiovascular function in six healthy men, aged 70–76. Participants were administered 1 mg of RAPA daily for 8 weeks in an open-label trial. The study found the treatment to be safe and well-tolerated. While most measures of systolic function, such as ejection fraction ($p=0.75$), did not change significantly, cardiac MRI revealed statistically significant improvements in key parameters of diastolic function. Specifically, researchers observed an improved peak left-ventricular filling rate ($p=0.014$), increased maximum local blood acceleration ($p=0.004$), and greater total transmitral forward blood volume ($p=0.033$). Additionally, endothelial function, measured by local thermal hyperemic response, showed a significant improvement at the 8-week mark ($p=0.020$). The authors conclude that these findings demonstrate RAPA's potential to ameliorate age-related diastolic and endothelial dysfunction, supporting the need for larger, placebo-controlled clinical trials.



